Analysis of Tumor Deposit At the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients with Gastric Cancer Who Received Proximal Gastrectomy
Launched by JICHAO QIN · Dec 8, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying patients with gastric cancer to understand more about tumor deposits at a specific area of the stomach called the fusion site of the right and left gastric mesentery. The trial focuses on patients who are scheduled to have a type of surgery known as proximal gastrectomy, which involves removing part of the stomach along with surrounding tissue to treat the cancer. Researchers aim to learn how tumor deposits may affect patients' outcomes after surgery.
To participate in this trial, individuals must be between 18 and 85 years old and have a confirmed diagnosis of primary gastric adenocarcinoma, which is a type of stomach cancer. They should also be classified as having a certain stage of cancer that has not spread widely. Participants will need to provide written consent to join the study. It's important to note that people who have had certain types of previous treatments or surgeries, or who have other serious health conditions, may not be eligible. This trial is currently not recruiting participants, but it represents an important step in understanding gastric cancer treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Aged older than 18 years and younger than 85 years
- • 2. Primary gastric adenocarcinoma confirmed by preoperative pathology result
- • 3. cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
- • 4. Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
- • 5. American Society of Anesthesiologists (ASA) class I, II, or III
- • 6. Written informed consent
- Exclusion Criteria:
- • 1. Negative preoperative biopsy
- • 2. Too late tumour stage or metastasis (cT4b/M1)
- • 3. BMI\>30 kg/m2
- • 4. previous neoadjuvant chemotherapy or radiotherapy
- • 5. Previous upper abdominal surgery
- • 6. Combined with other malignant diseases
- • 7. Reject operation
About Jichao Qin
Jichao Qin is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With expertise in trial design and execution, Jichao Qin focuses on innovative therapeutic areas, ensuring rigorous adherence to regulatory standards and ethical considerations. The organization actively collaborates with healthcare professionals and research institutions to facilitate the development of new treatments, fostering a culture of transparency and scientific integrity. Through a patient-centered approach, Jichao Qin aims to contribute significantly to the advancement of evidence-based medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported